Baker Bros. Advisors’s AVANIR PHARMACEUTICALS, INC CL A AVNR Stock Holding History

Baker Bros. Advisors’s Portfolio AVNR Stock Details AVNR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-38,513,713	Closed	-$653M	–	139
2014 Q4	$653M	Buy	38,513,713 +17,539,036	+84%	+$247M	6.66%	5
2014 Q3	$250M	Buy	20,974,677 +2,416,190	+13%	+$16.5M	3.15%	10
2014 Q2	$105M	Buy	18,558,487 +12,768,348	+221%	+$58.8M	1.28%	16
2014 Q1	$21.3M	Buy	5,790,139 +361,548	+7%	+$1.38M	0.27%	38
2013 Q4	$18.2M	Buy	5,428,591 +1,000,000	+23%	+$4.13M	0.26%	37
2013 Q3	$18.7M	Buy	4,428,591 +850,000	+24%	+$4.03M	0.27%	33
2013 Q2	$16.5M	Buy	+3,578,591	New	+$12.3M	0.33%	31

Baker Bros. Advisors's AVNR Position: Q1 2015 in Review

Baker Bros. Advisors sold out of AVANIR PHARMACEUTICALS, INC CL A (AVNR) in Q1 2015, closing a stake of 38,513,713 shares — an estimated $653M sold.

Baker Bros. Advisors first reported a position in AVNR in Q2 2013 and held it in 7 quarters. The position peaked at $653M in Q4 2014. 0 funds tracked by Wall St. Rank hold AVNR as of Q1 2015.

Baker Bros. Advisors reported no remaining AVANIR PHARMACEUTICALS, INC CL A position as of Q1 2015 after selling out during the quarter.
Baker Bros. Advisors sold 38,513,713 AVANIR PHARMACEUTICALS, INC CL A shares in Q1 2015, an estimated $653M.
Baker Bros. Advisors first reported a position in AVANIR PHARMACEUTICALS, INC CL A in Q2 2013 and held it in 7 quarters.
Baker Bros. Advisors's AVANIR PHARMACEUTICALS, INC CL A position peaked at $653M in Q4 2014.
0 funds tracked by Wall St. Rank held AVANIR PHARMACEUTICALS, INC CL A as of Q1 2015.

Based on Baker Bros. Advisors's 13F filing for Q1 2015, filed 15 May 2015.